Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor
October 23 2024 - 6:00AM
Klotho Neurosciences, Inc. (NASDAQ: KLTO), a leading biotechnology
company focused on developing cell and gene therapies for aging and
age-related diseases, is proud to announce the appointment of Dr.
Makoto Kuro-o to its Scientific Advisory Board.
Dr. Kuro-o, a distinguished Japanese physician-scientist, is
widely recognized as the pioneer behind the discovery of the Klotho
gene, often referred to as the "anti-aging gene." While conducting
groundbreaking research at the National Institute of Neuroscience
in Tokyo, Dr. Kuro-o and his team identified the Klotho gene while
studying mice engineered to overexpress a gene linked to premature
aging. This landmark discovery revealed that Klotho plays a key
role in regulating aging processes. Mice deficient in the Klotho
gene exhibited accelerated aging, while those with overexpression
of the gene experienced extended lifespans, positioning Klotho as a
potential therapeutic target for age-related conditions.
Klotho Neurosciences’ CEO, Dr. Joseph Sinkule, warmly welcomed
Dr. Kuro-o, expressing deep admiration for his pioneering
contributions to aging research. "Dr. Kuro-o’s discovery of the
Klotho gene revolutionized our understanding of the biology of
aging. His insights will be invaluable as we work to develop our
patent-protected secreted form of Klotho (s-KL) as a treatment for
neurodegenerative diseases, including ALS, Alzheimer’s, and
Parkinson’s disease. We are confident that his involvement will
significantly accelerate our efforts to bring s-KL-based therapies
to clinical trials and ultimately to patients."
In response to his appointment, Dr. Kuro-o expressed his
enthusiasm: "I am honored to join the Scientific Advisory Board at
Klotho Neurosciences. The innovative work being done with s-KL, the
company's patented secreted form of Klotho, is truly impressive. I
am excited to collaborate with the other members of the Scientific
Advisory Board to advance this promising therapeutic approach."
Dr. Kuro-o’s contributions to Klotho Neurosciences will support
the company’s mission to develop cutting-edge therapies that target
the biological mechanisms of aging and improve the treatment of
neurodegenerative diseases.
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a
biopharmaceutical company pioneering the development of innovative,
disease-modifying cell and gene therapies using a patented secreted
form of the anti-aging Klotho gene (s-KL) to transform the
treatment of neurodegenerative and age-related disorders such as
ALS, Alzheimer's, and Parkinson's disease. The company’s current
portfolio consists of its proprietary cell and gene therapy
programs using DNA and RNA as therapeutics and diagnostics. Other
assets include clinical-stage programs involving antibody biologics
targeting cancer and autoimmune diseases, and drug delivery via a
needle-free dry powder jet autoinjector called Nanoject. The
company is managed by a team of individuals and advisors who are
highly experienced in biopharmaceutical product development and
commercialization.
For more information, contact:
Eric BoydInvestor RelationsEmail: IR@klothoneuro.com Website:
www.klothoneuro.com
Forward-Looking Statements:
This press release contains forward-looking statements. These
statements are made under the “safe harbor” provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These
forward-looking statements generally are identified by the words
“believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result,”
and similar expressions. Without limiting the generality of the
foregoing, the forward-looking statements in this press release
include descriptions of the Company’s future commercial operations.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, such as the Company’s inability to implement its business
plans, identify and realize additional opportunities, or meet or
exceed its financial projections and changes in the regulatory or
competitive environment in which the Company operates. You should
carefully consider the foregoing factors and the other risks and
uncertainties described in the documents filed or to be filed by
the Company with the U.S. Securities and Exchange Commission (the
“SEC”) from time to time, which could cause actual events and
results to differ materially from those contained in the
forward-looking statements. Copies of these documents are available
on the SEC’s website, www.sec.gov. All information provided herein
is as of the date of this press release, and the Company undertakes
no obligation to update any forward-looking statement, except as
required under applicable law.
Klotho Neurosciences (NASDAQ:KLTO)
Historical Stock Chart
From Nov 2024 to Dec 2024
Klotho Neurosciences (NASDAQ:KLTO)
Historical Stock Chart
From Dec 2023 to Dec 2024